secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evolent Health, Inc. (EVH)
CIK:        0001628908
Form:       8-K
Filed at:   2023-05-23T23:59:59+00:00
Accession:  0001628908-23-000069
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evolent Health targets $1.95B revenue, $190M adj. EBITDA for 2023 at Investor Day
--------------------------------------------------------------------------------

- 2023 revenue outlook midpoint $1.95B; adjusted EBITDA midpoint $190M.
- Revenue CAGR of 39% from Q4 2019 to Q1 2023; Q1 2023 revenue $427.7M.
- Cross-sell opportunity of $50B out of $150B specialty TAM; revenue renewal rate ~110% in 2022.
- Performance Suite mature flow-through margins estimated at 12-18%; capital-light model emphasized.
- TTM adjusted EBITDA $132.6M; TTM revenue (ex-divested) $1.35B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628908/000162890823000069/0001628908-23-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628908/000162890823000069/evh-20230523.htm
  HTML page:      https://secwatch.observer/filing/0001628908-23-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer